"id:ID","uuid","studyVersion","studyAcronym","studyTitle","id","studyRationale"
"821","edc05273-dbf1-4b5f-ae3a-0aedc860b43f","2","H2Q-MC-LZZT","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
